Findings from EXTEND, "a multicentre, open-label, parallel group, superiority-design phase II randomized study conducted among patients with oligometastatic solid tumours" was recently presented at the European Society of Radiotherapy and Oncology (ESTRO) Congress in Stockholm. EXTEND is the first randomized study for oligometastatic kidney cancer, a phase II ASTROS trial "comparing metastasis-directed therapy followed by pembrolizumab or surveillance." The EXTEND trial thus emphasizes consideration of control arm with potential adaption to novel systemic therapies.
Click here to learn more about the EXTEND trial.
Source mentioned:
The histology-specific framing is important here — oligometastatic disease is not one biological situation, and metastasis-directed therapy should not be applied as if every limited spread pattern behaves the same. Patient selection, disease pace and systemic therapy control still decide whether local treatment adds anything meaningful. This is the kind of evidence the oncology brothers conversations tend to stress: treat the biology, not just the scan.
ReplyDeleteThe histology-specific basket framing of EXTEND is exactly right — an oligometastatic kidney cancer behaves nothing like an oligometastatic colorectal cancer, and lumping them together never served anyone. The control-arm conversation is equally honest; novel systemic therapies keep raising the bar that local treatment has to clear. "Treat the biology, not just the scan" is a line worth repeating in every tumor board.
ReplyDelete